Education
About Us
Working with TipRanks
Follow Us
Molecular Partners Ag (MOLN)
:MOLN
MOLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.36 - $7.60
Previous CloseN/A
Volume8.30K
Average Volume (3M)1.44K
Market Cap
$148.19M
Enterprise Value$66.22M
Total Cash (Recent Filing)$130.91M
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 25, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding40,374,640
10 Day Avg. Volume1,067
30 Day Avg. Volume1,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue29.67
Enterprise Value/Gross Profit-3.05
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$8.33Price Target Upside128.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsMolecular Partners announced that the previously planned Phase 0 imaging study for MP0712 is no longer necessary following discussions with the FDA, allowing the company to proceed directly into a Phase I dose escalation study.
Financial StabilityMolecular Partners has CHF 131M cash and cash equivalents, which will be sufficient to fund its runway well into the future.
Preclinical DataMolecular Partners Ag presented its second Radio-DARPin candidate targeting mesothelin for ovarian cancer, showing promising preclinical data.
Bears Say
Dose Escalation Risks3 investigator-assessed DLTs were recorded (2 in DR7 and 1 in DR8), and 1 DLT (fatal pulmonary hemorrhage in context of disseminated intravascular coagulation) in DR8 was confirmed by the Dose Escalation Review Committee, resulting in a TD decrease for subsequent patients in DR8.
Treatment ChallengesAntidrug antibodies (ADAs) were detected in 66% of patients, which coincided with reduced serum MP0533 exposure levels, posing a challenge to treatment efficacy.
Workforce RestructuringMOLN announced that the company intends to reduce its current workforce by no more than 40 positions, representing up to ~24% of all headcounts.
Molecular Partners News
MOLN FAQ
What was Molecular Partners Ag’s price range in the past 12 months?
Molecular Partners Ag lowest stock price was $3.36 and its highest was $7.60 in the past 12 months.
What is Molecular Partners Ag’s market cap?
Molecular Partners Ag’s market cap is $148.19M.
When is Molecular Partners Ag’s upcoming earnings report date?
Molecular Partners Ag’s upcoming earnings report date is Aug 25, 2025 which is in 18 days.
How were Molecular Partners Ag’s earnings last quarter?
Molecular Partners Ag released its earnings results on Mar 06, 2025. The company reported -$0.363 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.085.
Is Molecular Partners Ag overvalued?
According to Wall Street analysts Molecular Partners Ag’s price is currently Undervalued.
Does Molecular Partners Ag pay dividends?
Molecular Partners Ag does not currently pay dividends.
What is Molecular Partners Ag’s EPS estimate?
Molecular Partners Ag’s EPS estimate is -0.5.
How many shares outstanding does Molecular Partners Ag have?
Molecular Partners Ag has 40,374,640 shares outstanding.
What happened to Molecular Partners Ag’s price movement after its last earnings report?
Molecular Partners Ag reported an EPS of -$0.363 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 2.245%.
Which hedge fund is a major shareholder of Molecular Partners Ag?
Currently, no hedge funds are holding shares in MOLN
Molecular Partners Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.33 (128.22% Upside)
$8.33 (128.22% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.44%
12-Months-Change
Fundamentals
Return on Equity
-40.40%
Trailing 12-Months
Asset Growth
-22.61%
Trailing 12-Months
Company Description
Molecular Partners Ag
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$8.33
▲(128.22% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---